Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation
Jonathan P Piccini,Anders Ahlsson,Paul Dorian,A Marc Gillinov,Peter R Kowey,Michael J Mack,Carmelo A Milano,Nicolas Noiseux,Louis P Perrault,William Ryan,Jonathan S Steinberg,Pierre Voisine,Nathan H Waldron,Kevin J Gleason,Wilson Titanji,Richard D Leaback,Alexandra O'Sullivan,William G Ferguson,Stefano Benussi,NOVA-AF Investigators,Shuhab A Akhter,Martin Andreas,Manuel Castella,Malcolm Dalrymple-Hay,Ahmed El-Eshmawi,Mark Groh,Thorsten Hanke,Hugues Jeanmart,Marc Katz,Jock N McCullough,Spencer Melby,Jeffrey Miller,Matthew A Romano,Mihai Victor Podgoreanu,Vikas Sharma,Christian Shults,Nicholas Teman,Bryan A Whitson,Anders Wickbom,Prashanth Vallabhajosyula,Terrence Yau
DOI: https://doi.org/10.1016/j.jacep.2024.01.020
Abstract:Background: Postoperative atrial fibrillation (POAF) is associated with increased morbidity and mortality. Epicardial injection of botulinum toxin may suppress POAF. Objectives: This study sought to assess the safety and efficacy of AGN-151607 for the prevention of POAF after cardiac surgery. Methods: This phase 2, randomized, placebo-controlled trial assessed the safety and efficacy of AGN-151607, 125 U and 250 U vs placebo (1:1:1), for the prevention of POAF after cardiac surgery. Randomization was stratified by age (<65, ≥65 years) and type of surgery (nonvalvular/valve surgery). The primary endpoint was the occurrence of continuous AF ≥30 seconds. Results: Among 312 modified intention-to-treat participants (placebo, n = 102; 125 U, n = 104; and 250 U, n = 106), the mean age was 66.9 ± 6.8 years; 17% were female; and 64% had coronary artery bypass graft (CABG) only, 12% had CABG + valve, and 24% had valve surgery. The primary endpoint occurred in 46.1% of the placebo group, 36.5% of the 125-U group (relative risk [RR] vs placebo: 0.80; 95% CI: 0.58-1.10; P = 0.16), and 47.2% of the 250-U group (RR vs placebo: 1.04; 95% CI: 0.79-1.37; P = 0.78). The primary endpoint was reduced in the 125-U group in those ≥65 years of age (RR: 0.64; 95% CI: 0.43-0.94; P = 0.02) with a greater reduction in CABG-only participants ≥65 years of age (RR: 0.49; 95% CI: 0.27-0.87; P = 0.01). Rehospitalization and rates of adverse events were similar across the 3 groups. Conclusions: There were no significant differences in the rate of POAF with either dose compared with placebo; however, there was a lower rate of POAF in participants ≥65 years undergoing CABG only and receiving 125 U of AGN-151607. These hypothesis-generating findings require investigation in a larger, adequately powered randomized clinical trial. (Botulinum Toxin Type A [AGN-151607] for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery [NOVA]; NCT03779841); A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A [AGN 151607] Injections into the Epicardial Fat Pads to Prevent Post-Operative Atrial Fibrillation in Patients Undergoing Open-Chest Cardiac Surgery; 2017-004399-68).